2026/0147 - Invitation to Submit Proposals under Framework Agreements 2023/438 - Human Plasma Derivatives and 2023/671 - Miscellaneous Medicines for the Procurement of Plasma-Derived Medicines

This tender, identified as 2026/0147, is an invitation for proposals related to the procurement of plasma-derived medicines. The acquisition will be conducted under two existing framework agreements: 2023/438 for Human Plasma Derivatives and 2023/671 for Miscellaneous Medicines. The primary focus is on securing essential medicines derived from human plasma, which are critical for treating a range of serious medical conditions. This procurement process aims to ensure a reliable supply of these specialized and often life-saving treatments. Bidders are expected to submit proposals that align with the specifications and terms established within the referenced framework agreements. The tender process will involve evaluating offers based on criteria such as product quality, availability, pricing, and the supplier's capacity to meet the demand for these specific pharmaceutical products. Successful bidders will contribute to the continuity of critical healthcare services requiring plasma-derived therapies.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 447,413.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.